|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2000-8-15
|
|
pubmed:abstractText |
Brain drug targeting may be achieved by conjugating drugs, that normally do not cross the blood-brain barrier (BBB), to brain drug delivery vectors. The murine 83-14 MAb to the human insulin receptor (HIR) is a potential brain drug targeting vector that could be used in humans, if this MAb was genetically engineered to form a chimeric antibody. where most of the immunogenic murine sequences are replaced by human antibody sequence.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0724-8741
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
266-74
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:10801214-Animals,
pubmed-meshheading:10801214-Antibodies, Monoclonal,
pubmed-meshheading:10801214-Blood-Brain Barrier,
pubmed-meshheading:10801214-Brain,
pubmed-meshheading:10801214-Brain Chemistry,
pubmed-meshheading:10801214-CHO Cells,
pubmed-meshheading:10801214-Capillaries,
pubmed-meshheading:10801214-Chelating Agents,
pubmed-meshheading:10801214-Cricetinae,
pubmed-meshheading:10801214-Drug Delivery Systems,
pubmed-meshheading:10801214-Humans,
pubmed-meshheading:10801214-Hybridomas,
pubmed-meshheading:10801214-Indium Radioisotopes,
pubmed-meshheading:10801214-Injections, Intravenous,
pubmed-meshheading:10801214-Macaca mulatta,
pubmed-meshheading:10801214-Mice,
pubmed-meshheading:10801214-Pentetic Acid,
pubmed-meshheading:10801214-Radioligand Assay,
pubmed-meshheading:10801214-Receptor, Insulin,
pubmed-meshheading:10801214-Recombinant Fusion Proteins
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor.
|
|
pubmed:affiliation |
Department of Microbiology and Immunology, UCLA School of Medicine, Los Angeles, California 90095, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.
|
